SCAI

This channel contains news about the Society for Cardiac Angiography and Interventions (SCAI), including coverage of its annual meeting and links to recently released practice guidelines. SCAI is a leading resource in interventional cardiology and cath lab techniques and technologies.

News | Cardiovascular Business

Avoiding High-risk Cath Lab Procedures Does Not Necessarily Improve Hospital Scores

May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 202 ...

May 05, 2021

One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

Feature | Coronavirus (COVID-19) | By Dave Fornell, Editor

Third of COVID Patients With STEMI Heart Attacks Die

May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial ...

May 03, 2021

News | Cath Lab

Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

May 03, 2021

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #

News | Congenital Heart

Global registry Shows Longer Stent Minimizes Procedure Complications in Sinus Venosus Atrial Septal Defects

May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for ...

May 01, 2021

Videos | Structural Heart

VIDEO: Socioeconomic and Geographic Access to TAVR Programs is Limited

Ashwin Nathan M.D., a cardiology fellow at the Hospital of the University of Pennsylvania, presented a late-breaking ...

April 30, 2021

The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function.

Feature | Structural Heart | Dave Fornell, Editor

One-year Results of the Harmony Transcatheter Pulmonary Valve Trial Presented at SCAI 2021

April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve ...

April 30, 2021

The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).

Feature | Structural Heart

TAVR Access is Inequitable Based Socioeconomics Level and Geography

April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United ...

April 30, 2021

New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell

News | Cath Lab

Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American ...

April 29, 2021

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today.

News | Antiplatelet and Anticoagulation Therapies

Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

April 28, 2021

The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.

News | Radial Access | Dave Fornell, Editor

Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

April 28, 2021

Videos | Cardiogenic Shock

VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

April 28, 2021

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

News | Cath Lab

COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

April 28, 2021

A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab

SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

April 28, 2021 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus ...

April 28, 2021

News

North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms

April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the ...

April 20, 2021

The Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System. It is first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT) to stop severe pulmonary valve regurgitation caused by congenital heart disease.

Feature | Structural Heart | By Dave Fornell, Editor

FDA Clears First Device to Treat Right Ventricular Outflow Tract Congenital Heart Disease

March 26, 2021 — Today, the U.S. Food and Drug Administration (FDA) cleared the Medtronic Harmony Transcatheter ...

March 26, 2021